MAP2K7 and non-small cell lung carcinoma: The large multinational randomised control trial SELECT-1 compared docetaxel alone or in combination with the MEK inhibitor selumetinib in 510 patients with KRAS-mutant NSCLC, finding no significant difference in progression-free or overall survival [48].